标题: [英语,临床]Long-term efficacy of entecavir therapy in chronic hepatitis B [打印本页] 作者: StephenW 时间: 2011-5-18 03:11 标题: [英语,临床]Long-term efficacy of entecavir therapy in chronic hepatitis B
Journal of Viral Hepatitis
Early View (Online Version of Record published before inclusion in an
issue)
Summary. No studies have reported the long-term effects of entecavir
switching in patients with multidrug resistance who developed resistance
after lamivudine/adefovir sequential therapy. We evaluated the efficacy of
96 weeks of entecavir therapy in patients with resistance to
lamivudine/adefovir sequential therapy. In total, 33 patients with chronic
hepatitis B virus (HBV) infection with evidence of active viral replication
(HBV DNA levels ≥105 copies/mL) or a history of treatment failure to
lamivudine/adefovir sequential therapy between April 2007 and July 2009
were treated with entecavir (1.0 mg daily) for at least 48 weeks. The rates
of alanine transaminase (ALT) normalization and HBV DNA negativity were
66.7% (14/21) and 24.2% (8/33) at 48 weeks, respectively. The initial HBV
DNA level was the only factor that was inversely associated with serum HBV
DNA negativity after 48 weeks of entecavir therapy (P < 0.023). At 96
weeks, the rates of ALT normalization and HBV DNA negativity were 77.8%
(7/9) and 16.7% (3/18), respectively. Viral breakthrough occurred in 21.2%
(7/33) and 78.9% (15/19) of patients at 48 and 96 weeks, respectively.
Patients who achieved a HBV DNA level of <4 log10 copies/mL at 48 weeks
maintained a similar HBV DNA level and a normal ALT level until 96 weeks.
Entecavir monotherapy for 96 weeks was not efficacious for patients with
lamivudine/adefovir-resistant HBV. The initial HBV DNA level was the only
predictive factor for antiviral efficacy. However, patients who achieved a
HBV DNA level of <4 log10 copies/mL with a normal ALT level at 48 weeks
should maintain, rather than stop, entecavir therapy.
逻辑可能是这样的,没看到全文。
At 96 weeks, the rates of ALT normalization and HBV DNA negativity were 77.8% (7/9) and 16.7% (3/18), respectively. Viral breakthrough occurred in 21.2% (7/33) and 78.9% (15/19) of patients at 48 and 96 weeks, respectively.
所以:
Entecavir monotherapy for 96 weeks was not efficacious for patients with lamivudine/adefovir-resistant HBV.
---------------------------------------------------------------------------------------------
Patients who achieved a HBV DNA level of <4 log10 copies/mL at 48 weeks maintained a similar HBV DNA level and a normal ALT level until 96 weeks.
所以:
The initial HBV DNA level was the only predictive factor for antiviral efficacy. However, patients who achieved a HBV DNA level of <4 log10 copies/mL with a normal ALT level at 48 weeks should maintain, rather than stop, entecavir therapy.
标题的Long-term是96周,2年时间。 作者: kennyu 时间: 2011-5-18 22:06